The Viral Vector Core (VVC) is integrated into multiple cancer projects directed at the study of the disease process, therapy and the pre-clinical development of vaccines. VVC staff is active participants in the development of gene transfer technologies in the cancer field. The interaction with multiple investigators from various disciplines allows for cross-fertilization of ideas, technical advancements, and innovations in vector designs. The VVC's overall objective is to support investigators in the use of gene transfer technologies, including consultation with the PI and staff, development of novel vectors, collaborative testing of vectors generated for function and purity, and finally routine preparation including quality control. VVC staff and investigators are in close contact through all phases of vector design and generation, and the VVC serves as both a research and development facility for gene transfer studies and a service facility for routine vector preparations. As a part of the service the VVC will provide purified and concentrated preparations of recombinant adenovirus, adeno-associated virus, vaccinia, baculovirus and retrovirus (including lentivirus). This facility provides access to standard cell lines, expression plasmids, and stock of recombinant reporter viral vectors. The main responsibilities of the VVC are to: prepare recombinant vectors; perform relevant quality control; disseminate vectors; maintain a database of vector stocks available for use; maintain a database of expression vectors; develop new expression vectors as needed; develop novel methods for vector production; and assist in the design and development of novel vectors. The VVC serves the needs of numerous outside cancer investigators interested in both basic and applied research with gene transfer vectors, and is important for several reasons. First, by keeping abreast of many different gene transfer vectors, approaches, and applications, the scientific expertise of the VVC staff is strengthened. Second, serving a broad scope of users improves and fosters inter-collegiate communication with focused efforts at developing improved vectors and delivery methods. Finally, a continuum of new ideas from both outside and within the university, and through our consultants, insures that the HCCC community has access to, or is aware of, the ?state of the art?.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-20
Application #
9914240
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
20
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Keck, Kendall J; Breheny, Patrick; Braun, Terry A et al. (2018) Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery 163:232-239
Schoenfeld, Joshua D; Sibenaller, Zita A; Mapuskar, Kranti A et al. (2018) Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models. Redox Biol 14:417-422
Kelpsch, Daniel J; Tootle, Tina L (2018) Nuclear Actin: From Discovery to Function. Anat Rec (Hoboken) 301:1999-2013
Gupta, Gaurav; Kuppachi, Sarat; Kalil, Roberto S et al. (2018) Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant 18:245-252
Garje, Rohan; Chau, Justin J; Chung, Jina et al. (2018) Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. J Immunother 41:42-44
Ruiz Ciancio, Dario; Vargas, Mauricio R; Thiel, William H et al. (2018) Aptamers as Diagnostic Tools in Cancer. Pharmaceuticals (Basel) 11:
Triplette, Matthew; Crothers, Kristina; Mahale, Parag et al. (2018) Risk of lung cancer in lung transplant recipients in the United States. Am J Transplant :
Andrew, Megan; Kim, Yusung; Ginader, Timothy et al. (2018) Reduction of applicator displacement in MR/CT-guided cervical cancer HDR brachytherapy by the use of patient hover transport system. J Contemp Brachytherapy 10:85-90
Buchakjian, Marisa R; Ginader, Timothy; Tasche, Kendall K et al. (2018) Independent Predictors of Prognosis Based on Oral Cavity Squamous Cell Carcinoma Surgical Margins. Otolaryngol Head Neck Surg 159:675-682
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152

Showing the most recent 10 out of 1080 publications